19,629 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 19,629 shares of the medical research company's stock, valued at approximately $1,453,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $3,173,000. World Investment Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 1,660.7% in the 3rd quarter. World Investment Advisors LLC now owns 72,277 shares of the medical research company's stock worth $4,770,000 after purchasing an additional 68,172 shares in the last quarter. Wilmington Savings Fund Society FSB raised its holdings in shares of Edwards Lifesciences by 147.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company's stock valued at $601,000 after buying an additional 5,420 shares in the last quarter. Destination Wealth Management lifted its position in Edwards Lifesciences by 2.8% in the 3rd quarter. Destination Wealth Management now owns 7,012 shares of the medical research company's stock worth $463,000 after buying an additional 193 shares during the last quarter. Finally, Tidal Investments LLC boosted its stake in Edwards Lifesciences by 0.7% in the third quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company's stock worth $2,609,000 after buying an additional 275 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on EW. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $78.55.

Edwards Lifesciences Stock Up 0.5 %

EW stock traded up $0.36 during midday trading on Friday, hitting $71.56. The stock had a trading volume of 3,235,636 shares, compared to its average volume of 4,927,071. The business has a 50-day moving average of $71.31 and a two-hundred day moving average of $70.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $42.07 billion, a price-to-earnings ratio of 10.27, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the transaction, the vice president now directly owns 47,206 shares in the company, valued at $3,295,450.86. The trade was a 16.75 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock valued at $5,163,062 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.